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Mechanism of transforming growth factor-b1 signaling: Role has been well demonstrated in both human and experi-
of the mitogen-activated protein kinase. mental diabetic nephropathy. For instance, Yamamoto
Transforming growth factor-b1 (TGF-b1) regulates diverse et al have demonstrated progressive increase in the ex-biologic activities including cell growth, cell death or apoptosis,
pression of TGF-b1 mRNA in glomeruli of rats madecell differentiation, and extracellular matrix (ECM) synthesis.
diabetic by the administration of streptozotocin [6]. Fur-TGF-b1 is believed to be a key mediator of tissue fibrosis as
a consequence of ECM accumulation in pathologic states such thermore, increased glomerular TGF-b1 immunostaining
as progressive renal diseases including diabetic nephropathy. with concomitant increase in ECM proteins induced by
TGF-b1 actions are mediated by the heteromeric interactions TGF-b1 were observed in both diabetic rats and patientsof types I and II serine/threonine kinase receptors. Initiation of
with diabetic nephropathy [6]. A separate study by Naka-signaling requires binding of TGF-b1 to TGF-b type II recep-
mura et al also confirmed the increased glomerular ex-tor (TbR-II), a constitutively active serine/threonine kinase,
which subsequently transphosphorylates TGF-b type I receptor pression of TGF-b1 mRNA in the streptozotocin-induced
(TbR-I). However, the signaling pathway following the initial diabetic rat [7]. Treatment of streptozotocin-induced dia-
receptor interaction with ligand remains poorly understood.
betic mice with a neutralizing TGF-b antibody signifi-Much of current investigation, including in our laboratory, is
cantly attenuated the increase in TGF-b1 and ECM ex-now focused on the elucidation of the intracellular signaling
components that mediate TGF-b1 signals downstream of the pression [8]. Moreover, Sharma and Ziyadeh reported
cell-surface receptors. An emerging body of evidence impli- augmented TGF-b1 expression in the kidneys of two ex-
cates the mitogen-activated protein kinase (MAPK) as an im- perimental models of spontaneous diabetic BB rat and the
portant TGF-b1 signaling pathway.
NOD mouse [9]. In addition, elevated glucose concentra-
tions in vitro significantly increased TGF-b receptor num-
ber as well as mRNA and immunoreactive protein expres-
Transforming growth factor-b1 (TGF-b1) is a 25 kD sion in glomerular mesangial cells [10]. Collectively, these
homodimeric polypeptide, belonging to a superfamily of findings implicate a key role of TGF-b1 in the pathogene-
multifunctional cytokines, which participates in a broad
sis of both human and experimental diabetic nephropathy.
array of biologic activities such as normal development
Glomerulosclerosis, a central pathologic feature of pro-
and wound repair, as well as pathologic processes [1–5].
gressive renal diseases, is thought to represent the final
TGF-b1 regulates multiple cellular functions including
common response to injury, and the role of TGF-b1 in
inhibition and stimulation of cell growth, cell death or
this process is further demonstrated in other models ofapoptosis, and cellular differentiation. TGF-b1 is also a
glomerular diseases. For instance, increased TGF-b1 ex-potent inducer of extracellular matrix (ECM) protein
pression has been observed in the kidneys of patientssynthesis and has been implicated as the key mediator
and experimental animals with glomerulonephritis; sup-of fibrogenesis in various tissues [5]. In the kidney, the
pression of excess ECM deposition and glomeruloscle-critical role of TGF-b1 has been well recognized in sev-
rosis by neutralizing TGF-b1 antibody has been showneral renal diseases, including diabetic nephropathy, char-
in experimental glomerulonephritis [11, 12]. Further-acterized by progressive glomerular accumulation of
more, in vivo transfection of TGF-b1 gene into the ratECM, which leads to the development of glomeruloscle-
kidney has been shown to induce glomerulosclerosis [13].rosis [6–8]. Enhanced glomerular expression of TGF-b1
Similarly, development of glomerulosclerosis has been
described in mice that express the transgene for TGF-b1,
under the control of a murine albumin promoter (Alb/Key words: transforming growth factor-b1, signaling, mitogen-activated
protein kinase, ERK1/ERK2, p38. TGF-b1), and that elevated circulating levels of TGF-b1
[14]. Thus, an ever-growing body of data implicatesÓ 2000 by the International Society of Nephrology
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TGF-b1 as the key mediator in the pathogenesis of glo- ALK-5 is the predominant TGF-b signaling type I recep-
tor in most cell types [23].merulosclerosis, and much of our current investigations
Much progress has been made in identifying signalingare now being focused on the elucidation of TGF-b1
pathways for TGF-b by molecular cloning of the varioussignaling mechanisms.
receptors. We have previously reported the cloning of a
full-length rat TGF-b type II receptor cDNA and two dis-
TGF-b RECEPTORS tinct type I receptor cDNAs, namely ALK-5 and ALK-2,
TGF-b1 exerts its multiple biologic actions by the in- also known as Tsk7L [2, 16]. Our recent studies have iden-
teraction with two transmembrane serine/threonine ki- tified that there are variant forms of the TGF-b type I
nase receptors, types I and II, that are coexpressed by receptor ALK-5 [30]. From a neonatal rat kidney cDNA
most cells including glomerular mesangial and endothe- library, we have isolated three unique cDNA clones that
lial cells [15–17]. Initiation of signaling requires the bind- encode multiple receptor forms of ALK-5. Two of the
ing of TGF-b1 to TbR-II, a constitutively active serine/ rat cDNA clones encode membrane-spanning receptors
that differ in the C-terminal region of the extracellularthreonine kinase, resulting in the recruitment and phos-
domain. The third lacked the entire transmembrane andphorylation of TbR-I to produce a heteromeric signaling
the cytoplasmic serine/threonine domains and encodescomplex that in turn activates downstream signaling
a previously undescribed soluble form of TGF-b type Ipathways [18, 19].
receptor (sTbR-I) [30]. We have been able to clearly dem-Molecular cloning has revealed that a distinct type II
onstrate in vivo expression of a mRNA transcript encod-receptor exists for TGF-b1, and for members of the
ing the sTbR-I, and interestingly, the sTbR-I mRNA wasTGF-b superfamily, including activin and bone morpho-
expressed in greater abundance in the rat neonatal kid-genetic protein (BMP), and that the type II receptor is
ney compared with the adult kidney, as was the TbR-Icapable of binding its respective ligands directly and
mRNA abundance as previously reported, thus indi-interacting with different type I receptors [20–22]. To
cating a role for sTbR-I in renal development [2, 30].date, at least six distinct type I receptors of the TGF-b
Furthermore, sTbR-I is a functional protein capable ofsuperfamily, named activin receptor–like kinases (ALKs),
binding TGF-b1 ligand in the presence of TGF-b typehave been cloned. ALK-5 has been identified as the pre-
II receptor on the cell surface, as determined by affinitydominant TbR-I in most cell types and has been shown
cross-linking with 125I-labeled TGF-b1. Moreover, stud-to mediate TGF-b1 signaling [23]. ALK-1 and ALK-2
ies using a TGF-b-inducible luciferase reporter constructare thought to be activin type I receptors, but both have
p3TP-Lux reveal that this novel protein augmentedalso been demonstrated to bind TGF-b [24, 25]. ALK-4
TGF-b1 signaling [30]. Physiologic functions of thesealso appears to be an activin type I receptor [26]. ALK-3
variant receptor forms are not yet known, but their vari-and ALK-6 are thought to be type I receptors for BMP
able in vivo expression may represent a mechanism con-[27]. Features common to all type I receptors include a
ferring multiple cellular responses to TGF-b1. Moreover,cysteine-rich extracellular domain and a single trans-
the biologic importance of a soluble TbR-I is yet to bemembrane spanning domain. Furthermore, besides the
determined, but the findings here suggest that it maycharacteristic cytoplasmic serine/threonine kinase domain,
serve as a natural potentiator of TGF-b1 signaling. Thetype I receptors have a region between the transmem-
molecular cloning and identification of a naturally oc-brane and the kinase domains, containing a conserved
curring sTbR-I adds a new level of complexity to our
TSGSGSG motif, denoted the GS domain. Mutational
present knowledge of the TGF-b receptor system and
analyses have revealed that phosphorylation of serine
will facilitate further investigations to expand our under-
and threonine residues in the GS domain of the type I standing of the mechanism of TGF-b1 actions.
receptor by the type II receptor is essential for TGF-b1
signaling [28, 29].
MECHANISM OF TGF-b1 SIGNALINGTbR-I is thought to determine the specificity of the cel-
lular response to TGF-b1, whereas TbR-II determines the To understand the mechanisms involved in TGF-b1
ligand specificity. TbR-I alone is unable to bind TGF-b1, signaling from the cell membrane to the nucleus, it is
based on 125I-labeled TGF-b1 cross-linking studies, and crucial to unravel the intracellular events that provide a
TbR-II is unable to signal without TbR-I [18]. Thus, in- link between the activated cell surface TGF-b receptors
teraction of TGF-b type II receptor with different type and the downstream effects of TGF-b1, such as cell
I receptors to form the heteromeric signaling complex growth inhibition and matrix induction. With the identi-
may be a mechanism used to mediate the multiple TGF-b1 fication of the Smad family of signal-transducing proteins
actions and thus confer multifunctionality of TGF-b1. involved in mediating TGF-b1 signals downstream of
Although ALK-1, ALK-2, and ALK-5 have all been the transmembrane serine/threonine kinase receptors,
the focus of many investigators has centered on studiesdemonstrated to complex with ligand-bound TbR-II,
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of the Smad proteins. In particular, it is now known that tor for many cell types but has been demonstrated to
activate the ERK cascade rapidly in these cells includingSmad2 and Smad3 both act as signaling proteins and
transcription factors and are serine phosphorylated in a intestinal epithelial cells, hepatic stellate cells, and lung
fibroblasts, which suggests that the ERK pathway notTGF-b1-dependent fashion and associate with Smad4 to
translocate to the nucleus where they bind target sites only transduces mitogenic but also growth inhibitory sig-
nals [41–43]. TGF-b1-induced activation of ERK1/ERK2on specific gene promoters [31]. However, a growing
body of information is emerging regarding additional was associated with activation of the upstream Ras, Raf-1,
and MEK [42–44]. Ras is a highly conserved small molec-important intracellular signaling pathways for TGF-b1,
that may either signal independent of the Smads or con- ular weight GTP-binding protein that is capable of re-
cruiting and activating Raf-1 (MAPK kinase) which inverge and cross talk with the Smad signaling pathways.
turn activates MEK (MAPK kinase) in the ERK cascade.We and others have demonstrated the critical involve-
Given the rapid kinetics observed for TGF-b1-inducedment of the mitogen-activated protein kinase (MAPK)
activation of Ras and ERK (typically within 1–5 min),pathways in TGF-b1 signaling [32–35].
the effect of TGF-b1 on the ERK pathway is likely direct
and not secondary to activation of tyrosine kinase recep-
ROLE OF THE MITOGEN-ACTIVATED tors by secretion of growth stimulatory factors in re-
PROTEIN KINASE (MAPK) sponse to TGF-b1 [41–43]. Further, a dominant negative
The MAPK is a major signaling system used by eukary- of Ras (RasN17) completely blocked TGF-b-mediated
otic cells to transduce extracellular signals to intracellular activation of ERK1 and upregulation of cyclin-depen-
responses [36, 37]. Three major subgroups of the MAPK dent kinase (Cdk) inhibitors and resulted in reversal of
superfamily members have been identified to date: the the ability of TGF-b to decrease Cdk2 activity and cyclin
extracellular signal-regulated kinases 1 and 2 (ERK1 and A protein expression in intestinal epithelial cells [33, 45].
ERK2), also known as p44/p42 MAPKs, respectively; the Collectively, these studies indicate that Ras activation is
c-Jun N-terminal kinase/stress-activated protein kinase required for TGFb-mediated activation of ERK1 and that
(JNK/SAPK); and the p38 MAPK [36]. the Ras/ERK pathway is involved in TGF-b1-mediated
The signal transduction cascades involved in the acti- growth inhibition. TGF-b1 also exerts growth inhibitory
vation of MAPKs require a well-coordinated cascade of effects on glomerular mesangial and endothelial cells;
three protein kinase reactions that transduce signals by we have observed rapid activation of ERK1/ERK2 by
sequential phosphorylation and activation of the next TGF-b1 in these cells as well [16, 17, 35]. Moreover, both
kinase in their respective pathways. The MAPKs require the antiproliferative response and the activation of ERK1/
dual phosphorylation at the threonine and tyrosine sites ERK2 are blocked by dominant negative mutant TGF-b
type II receptor, suggesting that the ERK pathway isby MAPK kinases (the MEKs and MKKs that are spe-
also involved in TGF-b1-mediated growth inhibition incific for ERK, JNK, and p38 MAPK), which are in turn
glomerular mesangial and endothelial cells [17, 35].activated by MAPK kinase kinases (MKKKs) through
The multifunctional nature of TGF-b1 imparts diverseserine/threonine phosphorylation (36). The MAPK cas-
and sometimes opposing biologic effects on different cellcades display evolutionary conservation and are consid-
types, and thus TGF-b1 may stimulate rather than inhibitered to play essential roles in the signal transduction of
cell growth depending on the cellular context. As a casemany biologic events, such as the regulation of cell growth,
in point, we have recently reported the requirement ofdifferentiation, and apoptosis, and cellular responses to
the ERK pathway in signaling antiapoptotic effects ofenvironmental stresses. TGF-b1 has been demonstrated
TGF-b1 to promote cell survival of macrophages (32).in various cell types to be capable of activating each of
Murine macrophages (RAW 264.7) undergo apoptosisthe three major MAPK members.
following serum deprivation, as determined by DNA lad-
dering assay. However, apoptosis is prevented in serum-
TGF-b1-INDUCED ACTIVATION deprived macrophages by treatment with exogenous
OF ERK1 AND ERK2 TGF-b1. Using stably transfected RAW 264.7 cells ex-
The best characterized of the MAPKs is the ERK1/ pressing kinase-deleted dominant negative mutant TbR-II,
ERK2 cascade, which is the prototypical MAPK pathway we demonstrated that this protective effect by TGF-b1 is
activated by mitogenic growth factor stimulation of re- completely abrogated. We also show that TGF-b1 rap-
ceptor tyrosine kinases, whereas JNK/SAPK and p38 idly induces ERK1/ERK2 activities in a time-dependent
MAPK are activated predominantly by stress stimuli, manner up to 4 hours after stimulation. Blockade of the
such as ultraviolet light, inflammatory cytokines, and ERK pathway by either the expression of a dominant nega-
osmotic shock agents [38–40]. However, it is becoming tive of ERK2 or by a specific inhibitor of ERK (MEK1
evident that MAPKs play many different roles to regu- inhibitor, PD098059) abolished this protective effect of
TGF-b1 [32]. Taken together, our data demonstrate forlate many cellular responses. TGF-b1 is a growth inhibi-
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the first time that TGF-b1 is an inhibitor of apoptosis p38 MAPK phosphorylation on stimulation with TGF-b1
(within 5 to 15 minutes) in cultured rat glomerular mes-in cultured macrophages and may serve as a cell survival
factor through TbR-II-mediated signaling and down- angial cells [35]. Conversely, no appreciable increases in
the phosphorylation of p38 MAPK in glomerular endo-stream intracellular ERK-dependent pathway. Apopto-
sis in vivo is followed almost inevitably by rapid uptake thelial cells were found within the same time periods (up
to 4 hours) of TGF-b1 treatment (unpublished data).into adjacent phagocytic cells and represents a critical
process in tissue remodeling, regulation of immune re- Given that TAK1 can also lead to activation of JNK and
in several cell types, including HepG2, Chinese hamstersponse, or resolution of inflammatory reactions. The im-
portance of TGF-b1 in the regulation of inflammation is ovary (CHO), and Madin-Darby canine kidney (MDCK)
cell lines, TGF-b1 has been shown to activate JNK, wewell demonstrated in TGF-b knockout mice that exhibit
severe and generalized inflammatory disorders [4]. Thus, also determined whether TGF-b1 induced JNK activa-
tion [57]. However, similar to findings in data reported bythe potential clinical importance of our findings is that
it would establish for macrophages a cellular defense Wang et al no apparent activation of JNK was observed
within the same time periods of TGF-b1 treatment inmechanism to be selectively spared from toxicity and cell
death, a process that would be critical in the resolution of both glomerular mesangial and endothelial cells [35, 57].
In our studies with rat glomerular mesangial cells, acti-inflammation. Survival of macrophages is required to
perform their duties of phagocytosis and elimination of vation of p38 MAPK by TGF-b1 was completely abro-
gated by dominant-negative inhibition of TbR-I, by trans-adjacent harmful or injured cells, including lymphocytes
that have undergone apoptosis, and that disorders that fection with a truncated TbR-IM construct lacking the GS
and the kinase domains, indicating that TbR-I is requiredcompromise macrophage survival could contribute to
chronic inflammatory diseases. for this TGF-b1 response. Interestingly, transfection with
a dominant negative TbR-II, using a kinase-deleted
TbR-IIM construct, failed to inhibit TGF-b1-induced p38ACTIVATION OF p38 MAPK INDUCED
MAPK phosphorylation. Further, TGF-b1 (2 ng/mL) stim-
BY TGF-b1: ROLE IN DIABETES
ulated[3H] leucine incorporation and mRNA for pro-a1(I)
The p38 MAPK was first isolated as 38 kD protein, chain of type I procollagen in both wild-type and TbR-IIM-
which was rapidly tyrosine phosphorylated by bacterial transfected cells. Other TGF-b1 responses such as dose-
lipopolysaccharide (LPS) stimulation (46). In contrast dependent induction of PAI-1 mRNA was completely
to the ERK pathway, p38 MAPK is not activated primar- abrogated in transfected cells carrying TbR-IIM. We had
ily by mitogens but by cellular stresses and inflammatory noted previously that both ERK1/ERK2 activation and
cytokines in various cell types. For instance, p38 MAPK antiproliferative response to TGF-b1 were blocked by
activation has been observed in response to environmen- TbR-IIM. Thus, our findings indicate that expression of
tal stress, such as heat shock and hyperosmolarity, and in dominant negative TbR-IIM selectively and completely
inflammatory responses, as in LPS-treated macrophages, blocks some TGF-b1 effects, such as growth inhibition
and tumor necrosis factor a (TNF-a)-stimulated neutro- and ERK activation, but not its effect on ECM synthesis
phils and human umbilical vein endothelial cells [46–49]. or p38 MAPK activation. Two earlier studies had sug-
In addition, several growth factors and cytokines have gested seemingly separate signaling pathways for TGF-b1-
now also been shown to be capable of inducing the acti- mediated growth inhibition and ECM induction. Chen et
vation of p38 MAPK, including granulocyte macrophage al overexpressed a dominant negative TbR-II in Mv1Lu
colony-stimulating factor, fibroblast growth factor, insu- cells and reported abolition of TGF-b1-mediated inhibi-
lin-like growth factor, and TGF-b1 [50]. tion of both cell proliferation and pRB phosphorylation,
TGF-b-activated kinase 1 (TAK1) is a member of the but not TGF-b1-mediated ECM induction [58]. Using
MKKK family that has been shown to participate in mutational analyses, Saitoh et al observed that phos-
TGF-b1-induced regulation of gene transcription [51]. phorylation of serine 172 and threonine 176 residues of
TAK1 is a potent activator of p38 MAPK and JNK/SAPK TbR-I was essential for TGF-b1-mediated growth inhibi-
[52]. Indeed, rapid activation of p38 MAPK and its direct tion but not ECM induction in Mv1Lu cells [28]. Indeed,
activator MKK6 in response to TGF-b1 has been demon- the apparent disparity observed in all these studies may
strated in C2C12 cells and expression of a dominant be a result of differing threshold levels of receptor activ-
negative of MKK6 or TAK1 inhibited TGF-b-induced ity and signal transduction required for the various
transcriptional activation and p38 MAPK activation [53]. TGF-b1 actions. Nevertheless, based on the associated
Despite growing evidence that TGF-b1 induces activation findings that dominant negative TbR-IIM failed to block
of p38 MAPK in a number of cell types such as fibro- TGF-b1-mediated induction of pro-a1(I) type I procolla-
blasts, neutrophils, and smooth muscle cells, paucity of gen and p38 MAPK activation, we posed the question
data exists for glomerular mesangial and endothelial cells whether the p38 MAPK pathway was involved in mediat-
ing TGF-b1-induced pro-a1(I) procollagen mRNA ex-[54–56]. We have observed that TGF-b1 rapidly induces
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M, Allen R, Sidman C, Proetzel F, Calvin D, Annunziata N,pression. In the presence of a specific inhibitor of p38,
Doetschman T: Targeted disruption of the mouse transforming
SB203580, exogenous TGF-b1 was unable to induce pro- growth factor-b1 gene results in multifocal inflammatory disease.
a1(I) type I procollagen mRNA expression in rat glo- Nature 359:693–699, 1992
5. Border WA, Noble NA: Transforming growth factor b in tissuemerular mesangial cells [35]. Thus, our data demonstrate
fibrosis. N Engl J Med 331:1286–1292, 1994involvement of the p38 MAPK in TGF-b1 signaling path- 6. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border
way in glomerular mesangial cells. Furthermore, our WA: Expression of transforming growth factor b is elevated in
human and experimental diabetic nephropathy. Proc Natl Acadfindings suggest that p38 MAPK functions as a compo-
Sci USA 90:1814–1818, 1993nent in the signaling of ECM induction by TGF-b1. 7. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino
Reports in the literature suggesting a possible role of Y, Koide H: mRNA expression of growth factors in glomeruli
from diabetic rats. Diabetes 42:450–456, 1993p38 MAPK cascade in diabetic complications are only be-
8. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-bginning. For instance, Igarashi et al recently reported acti- by anti-TGF-b antibody attenuates kidney hypertrophy and the
vation of p38 MAPK in rat aortic smooth muscle cells by enhanced extracellular matrix gene expression in streptozotocin-
induced diabetic mice. Diabetes 45:522–530, 1996hyperglycemia and in aorta from streptozotocin-induced
9. Sharma K, Ziyadeh FN: Renal hypertrophy is associated withdiabetic rats, implicating involvement of the p38 MAPK upregulation of TGF-b1 gene expression in diabetic BB rat and
pathway in the development of diabetic vascular compli- NOD mouse. Am J Physiol 267:F1094–F1101, 1994
10. Riser BL, Ladson-Wofford S, Sharba A, Cortes P, Drake K,cations [59]. Interestingly, their studies showed that even
Guerin C, Yee J, Choi ME, Segarini PR, Narins R: TGF-b recep-moderately elevated glucose concentration (16.5 mM) tor expression and binding in rat mesangial cells by glucose and
significantly increased p38 MAPK but not ERK1/ERK2 cyclic mechanical strain. Kidney Int 56:428–439, 1999
11. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevatedactivities. Increased levels of phosphorylated p38 MAPK
expression of transforming growth factor-b and proteoglycan pro-were also detected in glomeruli isolated from rats with
duction in experimental glomerulonephritis. J Clin Invest 86:453–
streptozotocin-induced diabetes compared with nondia- 462, 1990
12. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahtibetic control rats and insulin-treated diabetic rats [60].
E: Suppression of experimental glomerulonephritis by antiserumIn addition, activation of p38 MAPK was detected in
against transforming growth factor-b1. Nature 346:371–374, 1990
isolated glomeruli exposed to high-glucose concentra- 13. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E:
Glomerulosclerosis induced by in vivo transfection of transformingtions of 25 mmol/L compared with 5.6 mmol/L [60].
growth factor-b or platelet-derived growth factor gene into the ratIn summary, an ever-growing body of evidence sup-
kidney. J Clin Invest 92:2597–2601, 1993
ports TGF-b1 as the key mediator in the pathogenesis 14. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bo¨ttinger
of diabetic nephropathy and the MAPKs as important EP, Klotman PE, Thorgeirsson SS: Transgenic mice with in-
creased plasma levels of TGF-b1 develop progressive renal disease.TGF-b1 signaling pathways involved in tissue injury re-
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